October 27, 2020 — Today, the U.S. Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch. The FDA initially approved Sklice (ivermectin) lotion, 0.5% for the treatment of head lice infestation in patients 6 months of age and older as a prescription drug in February 2012.
“The Rx-to-OTC switch process aims to promote public health by increasing consumer access to drugs that would otherwise only be available by prescription,” said Theresa Michele, M.D., acting director of the Office of Nonprescription Drugs in the FDA’s Center for Drug Evaluation and Research. “Today’s approval expands access to another effective topical treatment for the thousands of people with head lice.”
Rx-to-OTC switches are generally initiated by the manufacturer of the prescription drug. For a drug to switch from prescription to nonprescription status, the data provided must demonstrate that the drug is safe and effective when used as directed in the proposed labeling. The manufacturer must show that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional.
In the United States, it is estimated that between 6 and 12 million cases of head lice infestation occur each year in children 3 to 11 years of age, according to the U.S. Centers for Disease Control and Prevention. Head lice are most common among preschool children attending child care, elementary school children and members of a household where children have lice.
Sklice is a single-use lotion with ivermectin 0.5% as the active ingredient, for the topical treatment of head lice infestations in patients 6 months of age and older. Sklice is for external use only and should only be used on the scalp and dry hair in accordance with label directions. Sklice is not approved for any other use.
Sklice will be marketed in the United States as a nonprescription drug and will no longer be available as a prescription drug. Consumers should read and follow the Drug Facts label for the nonprescription product. Patients who currently use prescription versions of this product should talk to their healthcare professional.
The FDA granted the approval of nonprescription Sklice (ivermectin) lotion, 0.5% for the topical treatment of head lice infestations in patients 6 months of age and older to Arbor Pharmaceuticals LLC.
Sklice, and its active ingredient ivermectin, have not been shown to be safe or effective for the treatment or prevention of COVID-19 and they are not FDA-approved for this use. The public can alert the FDA of any product being marketed or distributed with claims to prevent or cure COVID-19 by reporting the product to [email protected] or 1-888-INFO-FDA (1-888-463-6332 ).
Posted: October 2020
- Sanofi Announces FDA Approval of Sklice Lotion for the Treatment of Head Lice – February 7, 2012
- Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA – June 15, 2011
Sklice (ivermectin) FDA Approval History
Source: Read Full Article